Under copyright Constraint(s) on Use: This work is protected by the U.S. Copyright Law (Title 17, U.S.C.). Use of this work beyond that allowed by "fair use" requires written permission of the UC Regents. Responsibility for obtaining permissions and any use and distribution of this work rests exclusively with the user and not the UC San Diego Library. Inquiries can be made to the UC San Diego Library program having custody of the work. Use: This work is available from the UC San Diego Library. This digital copy of the work is intended to support research, teaching, and private study.
Rights Holder and Contact
UC Regents
Description
Dr. Kabakoff earned his Bachelor of Arts in Chemistry from Case Western Reserve University, his Ph.D. in Organic Chemistry from Yale University, and post-doctoral research at the University of California San Diego. He held senior executive positions with Syntex, Hybritech, Inc., Corvas International, Dura Pharmaceuticals and Spiros Development Corp. Dr. Kabakoff co-founded Salmedix and subsequently negotiated its acquisition by Cephalon, Inc. He has over 30 years of experience leading technology and product development programs in the pharmaceutical, biopharmaceutical and drug delivery fields. He served as an Executive Partner with Sofinnova Ventures, Chairman of Trius Therapeutics, Chairman of Amplimmune, Inc., and Director of InterMune, Inc. and Allylix, Inc. Born digital Special Collections & Archives, UC San Diego, La Jolla, 92093-0175 (https://lib.ucsd.edu/sca) At the time of this interview, Dr. Kabakoff served in senior executive positions at Dura Pharmaceuticals Inc. Kabakoff, David. Interview conducted by Mark Jones, May 14 and June 29, 1997. The San Diego Technology Archive (SDTA), UC San Diego Library, La Jolla, CA.
Type
text
Identifier
ark:/20775/bb0651267k
Language
English
Subject
Pharmaceutical industry--Management Life sciences Corvas Pharmaceuticals Syntex Pharmaceuticals Hybritech, Inc San Diego (Calif.)
If you're wondering about permissions and what you can do with this item, a good starting point is the "rights information" on this page. See our terms of use for more tips.
Share your story
Has Calisphere helped you advance your research, complete a project, or find something meaningful? We'd love to hear about it; please send us a message.
